Skip to content

Clinical anxiolytic effect of Sitadi Agada and Imipramine (TCAs) in the management of Generalized Anxiety Disorders

Comparative evaluation of clinical anxiolytic efficacy of Sitadi Agada and Imipramine (TCAs) in the management of Generalized Anxiety Disorders (GAD)- A reverse Pharmacology approach.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046915
Enrollment
30
Registered
2022-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

None listed

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a)Patient willing to sign the consent form. b)Patients of either sex with age between 18 to 60 years. c)Patient fulfilling the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM â?? IV). e)Patient who score at least 14 on the Hamilton Anxiety Rating Scale (HARSâ?? A) at baseline visit.

Exclusion criteria

Exclusion criteria: a)Patient who suffers Anxiety due to direct physiological effect of a substance (e.g. alcohol etc) or a general medical condition (e.g. Hyperthyroidism). b)Occurrence of anxiety exclusively during mood disorder, a psychotic disorder or a pervasive development disorder. c)Patients having history of chronic diseases like Diabetes Mellitus, Ischemic Disease, Dyslipidemia, Hypertension, Malignancies, Chronic Renal Failure, Any Endochrinological disorders etc. will be excluded. d)Patients who have completed participation in any other clinical trial during the past six months. e)Pregnant or lactating women. f)Any other condition which the investigator thinks may jeopardize the study. g)Patients receiving Anxiolytic Drugs will be excluded.

Design outcomes

Primary

MeasureTime frame
Decreases the score of Hamilton Anxiety Rating Scale (HARSâ?? A) in the Generalized Anxiety Disorders Patient.Timepoint: 30 Days

Secondary

MeasureTime frame
1)To assess the grade of anxiety in Generalized anxiety disorders patient with the help of Hamilton Anxiety Rating Scale (HARSâ?? A). 2) To assess the efficacy of Sitadi Agada on the grade of a Anxiety.Timepoint: 30 days

Countries

India

Contacts

Public ContactDr Houserao Anandrao Patil Jadhav

Mahatma Gandhi Ayurved College, Hospital & Research Centre,Salod (H), Wardha.

dr.nilima_wadnerwar@rediffmail.com8275399319

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026